StockData
Travere Therapeutics, Inc. logo

Travere Therapeutics, Inc. (TVTX) stock

TVTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 6/30751% above fair value
$51.10+1.40 (+2.82%)

Close on Nov 17, 2026Market cap $4.82BP/E –Yield –

Travere Therapeutics profit margin

Profit margin (net margin) is net income as a percentage of revenue.

Travere Therapeutics's profit margin for the twelve months ending Jun 30, 2026 was -7.4%. For fiscal 2026 it was -5.2%, against -137.9% the year before. The highest annual figure on record is 117.4% in fiscal 2016.

Annual profit margin

PeriodPeriod endValueChange (pts)
FY2026Dec 31, 2025-5.2%+132.7
FY2025Dec 31, 2024-137.9%−61.2
FY2024Dec 31, 2023-76.7%+177.7
FY2023Dec 31, 2022-254.4%−117.8
FY2022Dec 31, 2021-136.6%−51.2
FY2021Dec 31, 2020-85.4%−1.9
FY2020Dec 31, 2019-83.5%−21.0
FY2019Dec 31, 2018-62.5%−24.0
FY2018Dec 31, 2017-38.6%−2.7
FY2017Dec 31, 2016-35.9%−153.2
FY2016Dec 31, 2015117.4%+510.7
FY2015Dec 31, 2014-393.4%–

Quarterly profit margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2027Jun 30, 2026-20.5%−9.4
Q1 FY2027Mar 31, 2026-29.2%+21.3
Q4 FY2026Dec 31, 20252.1%+82.7
Q3 FY2026Sep 30, 202515.6%+102.7
Q2 FY2026Jun 30, 2025-11.1%+119.0
Q1 FY2026Mar 31, 2025-50.4%+278.4
Q4 FY2025Dec 31, 2024-80.6%+119.5
Q3 FY2025Sep 30, 2024-87.1%−493.5
Q2 FY2025Jun 30, 2024-130.1%+135.9
Q1 FY2025Mar 31, 2024-328.9%−49.4
Q4 FY2024Dec 31, 2023-200.1%+24.2
Q3 FY2024Sep 30, 2023406.3%+654.5
Q2 FY2024Jun 30, 2023-266.0%−31.9
Q1 FY2024Mar 31, 2023-279.5%+45.0
Q4 FY2023Dec 31, 2022-224.4%−134.3
Q3 FY2023Sep 30, 2022-248.1%−195.9
Q2 FY2023Jun 30, 2022-234.1%−162.7
Q1 FY2023Mar 31, 2022-324.5%−210.9
Q4 FY2022Dec 31, 2021-90.1%+148.5
Q3 FY2022Sep 30, 2021-52.2%−8.2
Q2 FY2022Jun 30, 2021-71.4%−17.6
Q1 FY2022Mar 31, 2021-113.6%−115.3
Q4 FY2021Dec 31, 2020-238.6%−173.7
Q3 FY2021Sep 30, 2020-44.1%+38.1
Q2 FY2021Jun 30, 2020-53.8%+32.7
Q1 FY2021Mar 31, 20201.7%+105.2
Q4 FY2020Dec 31, 2019-64.8%−47.8
Q3 FY2020Sep 30, 2019-82.2%+51.7
Q2 FY2020Jun 30, 2019-86.6%−32.5
Q1 FY2020Mar 31, 2019-103.6%−55.7
Q4 FY2019Dec 31, 2018-17.0%+24.7
Q3 FY2019Sep 30, 2018-133.9%−89.8
Q2 FY2019Jun 30, 2018-54.0%−19.9
Q1 FY2019Mar 31, 2018-47.8%−14.8
Q4 FY2018Dec 31, 2017-41.8%−18.7
Q3 FY2018Sep 30, 2017-44.1%+65.2
Q2 FY2018Jun 30, 2017-34.1%–
Q1 FY2018Mar 31, 2017-33.0%–
Q4 FY2017Dec 31, 2016-23.0%–
Q3 FY2017Sep 30, 2016-109.3%–

More Travere Therapeutics figures

See a number that looks wrong?